Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.44
BIIB's Cash-to-Debt is ranked lower than
89% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. BIIB: 0.44 )
Ranked among companies with meaningful Cash-to-Debt only.
BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 4.45 Max: No Debt
Current: 0.44
Equity-to-Asset 0.54
BIIB's Equity-to-Asset is ranked lower than
65% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIIB: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.77 Max: 0.96
Current: 0.54
0.48
0.96
Interest Coverage 18.44
BIIB's Interest Coverage is ranked lower than
81% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 18.44 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 18.44  Med: 42.88 Max: 134.66
Current: 18.44
18.44
134.66
Piotroski F-Score: 5
Altman Z-Score: 6.16
Beneish M-Score: -2.48
WACC vs ROIC
4.67%
25.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 41.59
BIIB's Operating Margin % is ranked higher than
96% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. BIIB: 41.59 )
Ranked among companies with meaningful Operating Margin % only.
BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 24.59  Med: 33.48 Max: 45.44
Current: 41.59
24.59
45.44
Net Margin % 30.17
BIIB's Net Margin % is ranked higher than
93% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. BIIB: 30.17 )
Ranked among companies with meaningful Net Margin % only.
BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 24.74 Max: 32.95
Current: 30.17
19.11
32.95
ROE % 30.27
BIIB's ROE % is ranked higher than
96% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. BIIB: 30.27 )
Ranked among companies with meaningful ROE % only.
BIIB' s ROE % Range Over the Past 10 Years
Min: 10.06  Med: 20.75 Max: 35.15
Current: 30.27
10.06
35.15
ROA % 16.05
BIIB's ROA % is ranked higher than
95% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. BIIB: 16.05 )
Ranked among companies with meaningful ROA % only.
BIIB' s ROA % Range Over the Past 10 Years
Min: 7.43  Med: 14.4 Max: 22.42
Current: 16.05
7.43
22.42
ROC (Joel Greenblatt) % 140.33
BIIB's ROC (Joel Greenblatt) % is ranked higher than
95% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. BIIB: 140.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.17  Med: 90.54 Max: 189.7
Current: 140.33
54.17
189.7
3-Year Revenue Growth Rate 21.60
BIIB's 3-Year Revenue Growth Rate is ranked higher than
74% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BIIB: 21.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.1  Med: 21.6 Max: 78.2
Current: 21.6
-15.1
78.2
3-Year EBITDA Growth Rate 28.10
BIIB's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. BIIB: 28.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25 Max: 127.9
Current: 28.1
0
127.9
3-Year EPS without NRI Growth Rate 29.40
BIIB's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. BIIB: 29.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66  Med: 34.9 Max: 205.2
Current: 29.4
-66
205.2
GuruFocus has detected 2 Warning Signs with Biogen Inc $BIIB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIIB's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:REGN, OTCPK:SHPGF, OTCPK:CSLLY, NAS:VRTX, OTCPK:ALIOY, NAS:ALXN, NAS:INCY, NAS:GILD, OTCPK:GIKLY, NAS:BMRN, NAS:CELG, OTCPK:GMXAY, OTCPK:UCBJY, OTCPK:NVZMY, NAS:JAZZ, NAS:ALKS, NAS:SGEN, NAS:TSRO, NAS:ALNY, NAS:EXEL » details
Traded in other countries:BIIB.Austria, BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Headquarter Location:USA
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and is launching Spinraza with partner Ionis.

Top Ranked Articles about Biogen Inc

Jeff Ubben Buys 1, Sells 1 in 1st Quarter ValueAct leader to step down from CIO role
Jeff Ubben (Trades, Portfolio)’s ValueAct Holdings bought Bioverativ Inc. (NASDAQ:BIVV) and sold Allison Transmission Holdings Inc. (NYSE:ALSN) during the first quarter. Read more...
Ray Dalio Buys General Electric, Biogen, Walt Disney The guru's top 1st-quarter purchases
Ray Dalio (Trades, Portfolio) founded Greenwich, Connecticut-based hedge fund Bridgewater Associates in 1975. He manages a portfolio composed of 236 stocks with a total value of $8.818 billion. During the first quarter the guru bought shares in the following stocks: Read more...
BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience
Richard Pzena Invests in 3 Health Care Companies Guru releases 1st-quarter portfolio
Richard Pzena (Trades, Portfolio) gained 14 new holdings during the first quarter. Among them were three health care stocks, including Mylan NV(NASDAQ:MYL), Cardinal Health Inc. (NYSE:CAH) and Biogen Inc. (NASDAQ:BIIB). Read more...
Weekly Top Insider Buys Highlights Largest transactions were for Salesforce.com, Synchrony Financial, American Airlines Group and Biogen
Salesforce.com Inc. (NYSE:CRM), Synchrony Financial (NYSE:SYF), American Airlines Group Inc. (NASDAQ:AAL) and Biogen Inc. (NASDAQ:BIIB) were the largest insider buys for the week of May 5. Read more...
The 4 Principles That Drive PRIMECAP The firm has delivered above-average results with fundamental research, undiscovered value and more
Three colleagues left an established fund management company in the mid-1980s determined to set up their own firm, PRIMECAP Management (Trades, Portfolio) Co., which they would run their own way. Read more...
Spiros Segalas Sells American Tower, Biogen, Regeneron, Disney Guru's largest 1st-quarter trades
Spiros Segalas (Trades, Portfolio) manages the Harbor Capital Appreciation Fund. The portfolio is composed of 58 stocks with a total value of $24,593 million. During the first quarter, the guru sold shares in the following stocks: Read more...
Jeff Auxier Invests in Gilead, Wells Fargo, Apple The guru's repeat purchases in the last 2 quarters of 2016
Jeff Auxier (Trades, Portfolio) is the manager of Auxier Focus Fund. He manages a portfolio composed of 152 stocks with a total value of $460 million. In the fourth and third quarters of 2016 the guru bought shares in the following stocks: Read more...
Weekly CEO Buys Highlights Insiders buy American Assets, Plains GP Holdings, OPKO, Biogen and Aptar Group
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
New Features: Individual Portfolio Tracker and Value Screens Tracker A detailed discussion of 2 features on GuruFocus’ new home page
As discussed in a previous article, GuruFocus launched a new, user-friendly home page in February. The page contains two useful features: “Individual Portfolio Tracker” and the “Value Screens Tracker.” The former allows you to view snapshots of each of your portfolios and view alerts. If you scroll down to the “Value Screens” section, you will notice green and red icons on each of the tabs. These numbers track changes in the value screener record. Read more...

Ratios

vs
industry
vs
history
PE Ratio 17.44
BIIB's PE Ratio is ranked higher than
75% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.55 vs. BIIB: 17.44 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 21.7 Max: 100.96
Current: 17.44
10.8
100.96
Forward PE Ratio 14.12
BIIB's Forward PE Ratio is ranked higher than
73% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. BIIB: 14.12 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.44
BIIB's PE Ratio without NRI is ranked higher than
76% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.76 vs. BIIB: 17.44 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 21.7 Max: 103.15
Current: 17.44
10.8
103.15
Price-to-Owner-Earnings 26.46
BIIB's Price-to-Owner-Earnings is ranked higher than
61% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.51 vs. BIIB: 26.46 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.96  Med: 22.1 Max: 154.47
Current: 26.46
9.96
154.47
PB Ratio 5.20
BIIB's PB Ratio is ranked lower than
61% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BIIB: 5.20 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 4.16 Max: 8.84
Current: 5.2
1.71
8.84
PS Ratio 5.27
BIIB's PS Ratio is ranked higher than
69% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. BIIB: 5.27 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.37 Max: 10.99
Current: 5.27
2.58
10.99
Price-to-Free-Cash-Flow 29.02
BIIB's Price-to-Free-Cash-Flow is ranked lower than
51% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 28.96 vs. BIIB: 29.02 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.25  Med: 19.08 Max: 36.13
Current: 29.02
9.25
36.13
Price-to-Operating-Cash-Flow 16.24
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 25.50 vs. BIIB: 16.24 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.22  Med: 15.95 Max: 32.48
Current: 16.24
7.22
32.48
EV-to-EBIT 12.92
BIIB's EV-to-EBIT is ranked higher than
67% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. BIIB: 12.92 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 14.85 Max: 37.8
Current: 12.92
7.5
37.8
EV-to-EBITDA 10.64
BIIB's EV-to-EBITDA is ranked higher than
70% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. BIIB: 10.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.95 Max: 24.8
Current: 10.64
6.1
24.8
PEG Ratio 0.61
BIIB's PEG Ratio is ranked higher than
87% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 2.15 vs. BIIB: 0.61 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.81 Max: 35.41
Current: 0.61
0.31
35.41
Shiller PE Ratio 33.79
BIIB's Shiller PE Ratio is ranked higher than
69% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.27 vs. BIIB: 33.79 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 29.67  Med: 77.22 Max: 2372.5
Current: 33.79
29.67
2372.5
Current Ratio 2.29
BIIB's Current Ratio is ranked lower than
71% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BIIB: 2.29 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 4.16 Max: 20.41
Current: 2.29
0.78
20.41
Quick Ratio 1.98
BIIB's Quick Ratio is ranked lower than
70% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BIIB: 1.98 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.94 Max: 20.41
Current: 1.98
0.7
20.41
Days Inventory 230.44
BIIB's Days Inventory is ranked lower than
77% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. BIIB: 230.44 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 230.44
219.47
266.3
Days Sales Outstanding 47.52
BIIB's Days Sales Outstanding is ranked higher than
65% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. BIIB: 47.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 45.32 Max: 48.62
Current: 47.52
39.79
48.62
Days Payable 74.49
BIIB's Days Payable is ranked higher than
61% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. BIIB: 74.49 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 69.07  Med: 98.14 Max: 148.21
Current: 74.49
69.07
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. BIIB: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.1  Med: -0.3 Max: 30.9
Current: 3
-92.1
30.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 15.84
BIIB's Price-to-Tangible-Book is ranked lower than
85% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. BIIB: 15.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.07  Med: 4.85 Max: 24.42
Current: 15.84
0.07
24.42
Price-to-Intrinsic-Value-Projected-FCF 1.72
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.46 vs. BIIB: 1.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 1.65 Max: 12.97
Current: 1.72
0.05
12.97
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.61
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
92% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. BIIB: 0.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.98
BIIB's Price-to-Median-PS-Value is ranked higher than
50% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BIIB: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.93 Max: 13.27
Current: 0.98
0.05
13.27
Price-to-Peter-Lynch-Fair-Value 0.70
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
91% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. BIIB: 0.70 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.2 Max: 18.88
Current: 0.7
0.41
18.88
Price-to-Graham-Number 3.50
BIIB's Price-to-Graham-Number is ranked lower than
63% of the 190 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. BIIB: 3.50 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.07  Med: 2.81 Max: 33.65
Current: 3.5
0.07
33.65
Earnings Yield (Greenblatt) % 7.74
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. BIIB: 7.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 6.75 Max: 13.4
Current: 7.74
2.6
13.4
Forward Rate of Return (Yacktman) % 34.37
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
83% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. BIIB: 34.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.3  Med: 29.6 Max: 45.7
Current: 34.37
-1.3
45.7

More Statistics

Revenue (TTM) (Mil) $11,532.70
EPS (TTM) $ 15.97
Beta0.45
Short Percentage of Float1.14%
52-Week Range $205.43 - 307.33
Shares Outstanding (Mil)212.12

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 11,540 12,168 12,820
EPS ($) 19.86 21.77 22.67
EPS without NRI ($) 19.86 21.77 22.67
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.10%
Dividends per Share ($)
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 

More From Other Websites
2 Pharma Buyout Targets That May Surprise You Jun 27 2017
Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Jun 23 2017
Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive... Jun 23 2017
Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : June 22, 2017 Jun 22 2017
Futures: These 2 Big Breakouts Highlight New Market Leadership Jun 22 2017
[$$] Pharma recovers composure as price concerns ease Jun 21 2017
Biotech Breakouts: Biogen Spinoff Bioverativ In Buy Zone Jun 21 2017
Amgen An Undervalued Industry Leader Jun 21 2017
Amgen: In Defense of A Pipeline Jun 21 2017
Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : June 21, 2017 Jun 21 2017
Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017 Jun 20 2017
Updates on the Adcetris and Opdivo Combination Jun 20 2017
Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer Jun 20 2017
5 Most Profitable Big Pharma Stocks on the Market Right Now Jun 20 2017
US STOCKS-Wall St hits record highs on strong technology, health stocks Jun 19 2017
The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It Jun 19 2017
Biogen's stock jumps after UBS boosts rating, price target Jun 19 2017
Picks of Steel Jun 19 2017
Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress Jun 19 2017
Biogen: "The Underperformance Stops Here" Jun 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}